Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial.
Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, Jensen T, Parving HH, Thorsteinsson B, Tarnow L. Pedersen-Bjergaard U, et al. Among authors: kristensen pl. Diabetes Res Clin Pract. 2017 Jan;123:143-148. doi: 10.1016/j.diabres.2016.11.003. Epub 2016 Nov 16. Diabetes Res Clin Pract. 2017. PMID: 28012403 Clinical Trial.
Cognitive performance, symptoms and counter-regulation during hypoglycaemia in patients with type 1 diabetes and high or low renin-angiotensin system activity.
Høi-Hansen T, Pedersen-Bjergaard U, Andersen RD, Kristensen PL, Thomsen C, Kjaer T, Høgenhaven H, Smed A, Holst JJ, Dela F, Boomsma F, Thorsteinsson B. Høi-Hansen T, et al. Among authors: kristensen pl. J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):216-29. doi: 10.1177/1470320309343007. Epub 2009 Aug 28. J Renin Angiotensin Aldosterone Syst. 2009. PMID: 19717500 Free article.
Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial.
Pedersen-Bjergaard U, Kristensen PL, Beck-Nielsen H, Nørgaard K, Perrild H, Christiansen JS, Jensen T, Hougaard P, Parving HH, Thorsteinsson B, Tarnow L. Pedersen-Bjergaard U, et al. Among authors: kristensen pl. Lancet Diabetes Endocrinol. 2014 Jul;2(7):553-61. doi: 10.1016/S2213-8587(14)70073-7. Epub 2014 May 2. Lancet Diabetes Endocrinol. 2014. PMID: 24794703 Clinical Trial.
133 results